Methyl α-D-mannopyranoside for COVID-19
Methyl α-D-mannopyranoside has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Molecular Docking against SARS-CoV-2 Variants, Antiviral, Dynamics and Quantum Chemical Modeling of Mannopyranoside Derivatives, Moroccan Journal of Chemistry, doi:10.48317/IMIST.PRSM/morjchem-v11i04.42045 ,
Researchers worldwide are prompting their hard and soul effort to develop the best possible therapeutic options to eliminate vaccination-related difficulties to effectively manage SARS-CoV-2, which is now sweeping the world. The present study was undertaken to investigate the computational properties of methyl α-D-mannopyranoside and its designed derivatives to assess their thermophysical and biochemical parameters. The PASS prediction score was reported to be 0.233
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.